RxDoctor Payments Data

Joseph Zuckerman, MD

Orthopaedic Surgery · New York, NYNPI 1346230448

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $9,602,094 of the $9,865,480 with a category attached, or 97.3%. Exactech, Inc. accounts for 98.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $2,222,160 and has fallen 67.8% since, to $716,382 in 2025. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,865,480in general payments, 2019–2025

Across 191 payments — averaging $51,652 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exactech, Inc.$9.7M
  • Musculoskeletal Transplant Foundation Inc.$201K
  • Zimmer Biomet$141
  • Endo Pharmaceuticals Inc.$115

What the payments were for

  • Royalty or licence$9,602,09497%
  • Speaking & faculty fees$196,0002%
  • Travel & lodging$55,5541%
  • Food & beverage$11,8310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,865,480 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York

Medicare billing

Part B allowed, 2024
$319,531
Medicare patients
546
Services billed
1,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium30$624
Diclofenac Potassium11$134
Meloxicam18$55

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →